P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032

ABSTRACT:

SUBMITTER: Iyer S 

PROVIDER: S-EPMC10430937 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature